Tag: AbbVie
The Lancet on the PAF AbbVie case: AbbVie to face potentially groundbreaking case over Humira
Wilbert Bannenberg -
The Lancet interviewed the chair of the Pharmaceutical Accountability Foundation (Wilbert Bannenberg) about the recent verdict of the Amsterdam Court moving the case to the substantive issues. The court instructed AbbVie to answer on the PAF subpoena by 22 January 2025. PAF is very proud of our principle case...
PRESS RELEASE: Lawsuit against AbbVie for abuse of economic dominance and violation of human rights moves to substantive phase
Farma ter Verantwoording -
AbbVie's Humira pricing policy drained up to €1.2 billion from the Dutch healthcare system
AMSTERDAM, NETHERLANDS: Today the Amsterdam District Court ruled that the lawsuit filed by the Pharmaceutical Accountability Foundation (PAF) against drug manufacturer AbbVie may proceed to its merits.
In February 2023, PAF filed a lawsuit against AbbVie, alleging...
AbbVie overcharged the Dutch health care system by as much as €1.2 billion for Humira
Rosalind Turkie -
AMSTERDAM, THE NETHERLANDS: The Pharmaceutical Accountability Foundation (PAF) today brought a lawsuit against pharmaceutical company AbbVie for unfair, excessive pricing practices on its blockbuster medicine Humira(adalimumab).
AbbVie sold €2.3 billion worth of Humira in the Netherlands during its market monopoly (2004-2018). PAF calculated that AbbVie had overcharged the Dutch healthcare...
Licensed under Creative Commons (CC BY-NC-SA 4.0), The Pharmaceutical Accountability Foundation 2022